Prostate cancer update

Current Opinion in Oncology

Volumn 14, Issue 3, 2002, Pages 286-291

  Rini, Brian I ^a   Small, Eric J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABARELIX; ACID PHOSPHATASE PROSTATE ISOENZYME; ANTIANDROGEN; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CARBONATE; CLODRONIC ACID; DOXORUBICIN; ESTRAMUSTINE PHOSPHATE; ETOPOSIDE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROCORTISONE; LEUPRORELIN; MITOXANTRONE; PA 2024; PAMIDRONIC ACID; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT ANTIGEN; STRONTIUM; SULINDAC SULFONE; SURAMIN; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; VITAMIN D; ZOLEDRONIC ACID;

BONE PAIN; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; DENDRITIC CELL; DRUG EFFICACY; FATIGUE; GYNECOMASTIA; HORMONE DEPENDENCE; HORMONE RESISTANCE; HOT FLUSH; HUMAN; LIVER TOXICITY; MALE; NAUSEA; NEUTROPENIA; OSTEOPENIA; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SALVAGE THERAPY; SEXUAL DYSFUNCTION;

ANDROGEN ANTAGONISTS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DIPHOSPHONATES; HUMANS; IMMUNOTHERAPY; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 0036256059     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200205000-00006     Document Type: Review

References (27)

1. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer
2. Fatty fish consumption and risk of prostate cancer
3. Outcome for surgically staged localized prostate cancer treated with external beam radiation therapy
4. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the center for prostate disease research and cancer of the prostate strategic urologic research endeavor databases
5. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy
6. Natural history of progression after PSA elevation following radical prostatectomy
7. Chemotherapy in patients with prostate specific antigen-only disease after primary therapy for prostate carcinoma: A phase II trial of oral estramustine and oral etoposide
8. Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma
9. Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy
10. Sulindac and its derivatives: A novel class of anticancer agents
11. Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report
12. Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer
13. Intermittent androgen suppression for prostate cancer: Canadian prospective trial and related observations
14. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: Initial results of endocrinological and biochemical efficacies in patients with prostate cancer
15. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer
16. Bisphosphonate treatment inhibits the growth of prostate cancer cells
17. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer
18. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer
19. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells
20. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: A phase III study of the European Organization for Research and Treatment of Cancer Genitourinary Group
21. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points
22. Androgen receptor mutations in androgen independent prostate cancer (APICA) do not correlate with anti-androgen withdrawal response: Cancer and Leukemia Group B (CALGB) 9663
23. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer
24. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen
25. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group
26. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: Association with progression-free survival, pain end points, and survival
27. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: A randomised phase II trial